Linked Life Data

18248314

Source:http://linkedlifedata.com/resource/pubmed/id/18248314

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2008-2-5
pubmed:abstractText
Pramipexole is a non-ergoline dopamine agonist with a high selectivity for D(2) and D(3) receptors. Initially approved for Parkinson's disease, it was approved by the FDA and EMEA in 2006 for the treatment of idiopathic restless legs syndrome in adults. A single oral dose of pramipexole of between 0.125 and 0.750 mg, taken 2 - 3 h before bedtime, is usually able to control sensory symptoms and motor signs of restless legs syndrome. In clinical practice, tailoring pramipexole treatment based on demographic and clinical characteristics of patients is recommended. In addition, pramipexole seems to be safe and well tolerated. Augmentation, the most common side effect of levodopa, is less prevalent after treatment with pramipexole. In addition, the recurrence of unpleasant symptoms due to pramipexole is uncommon.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1742-5255
pubmed:author
pubmed:issnType
Print
pubmed:volume
4
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
225-35
pubmed:dateRevised
2009-11-16
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Clinical experience with pramipexole in the treatment of restless legs syndrome.
pubmed:affiliation
Santa Maria della Misericordia University Hospital, Sleep Disorder Center, Neurology and Clinical Neurophysiology, Udine, Italy. gigli@uniud.it
pubmed:publicationType
Journal Article, Review